<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818581</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000076</org_study_id>
    <nct_id>NCT03818581</nct_id>
  </id_info>
  <brief_title>Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes</brief_title>
  <official_title>Effect of Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes: A Randomized 3-month Clinical Trial Using a Sequential Parallel Comparison Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to determine the effect of suvorexant on subjective total sleep time&#xD;
      (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized&#xD;
      placebo-controlled trial for 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes results from a progressive insulin secretory defect on the background of&#xD;
      insulin resistance and is a growing pandemic and a leading cause of morbidity and mortality.&#xD;
      Sleep disturbance is one of the underappreciated and important features of Type 2 diabetes,&#xD;
      and may contribute to the development of the disease. In those with established Type 2&#xD;
      diabetes, there is emerging evidence from cross-sectional studies that sleep disturbance&#xD;
      affects glycemic control. Although cross-sectional studies suggest a relationship between&#xD;
      sleep disturbance and glycemic control in Type 2 diabetes, causality is best investigated by&#xD;
      interventional studies. Suvorexant has a comparatively benign side effect profile compared to&#xD;
      many of the hypnotic agents typically prescribed for insomnia. The investigators aim to&#xD;
      determine the effect of suvorexant on subjective total sleep time (TST), as well as&#xD;
      subjective wake after sleep onset, Insomnia Severity Index, HbA1c levels and insulin&#xD;
      sensitivity, inflammatory markers, and other subjective sleep endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Sequential Parallel Comparison Design: subjects will be randomized in a 1:2 ratio to suvorexant 10-20 mg or equivalent placebo for six weeks, followed by re-randomization of placebo non-responders to either suvorexant or placebo in a 1:1 design for six weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The participant, investigator, and clinical research coordinator will remain masked throughout the duration of the study. An unmasked research coordinator will be responsible for assessing mid-point outcomes on the sleep diaries and communicating with the pharmacy for re-randomization medication orders.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Total Sleep Time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total sleep time as reported on daily sleep diaries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Wake After Sleep Onset</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total time awake after sleep onset as reported on daily sleep diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>2 weeks</time_frame>
    <description>A validated tool to measure insomnia severity, on a scale of 0-28, with a higher score representing greater insomnia severity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insomnia</condition>
  <condition>Sleep Disorder</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Responders</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Non-responders Re-randomized to Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Non-responders Re-randomized to Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>10-mg or 20-mg Suvorexant capsules</description>
    <arm_group_label>Placebo Non-responders Re-randomized to Treatment</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo Non-responders Re-randomized to Placebo</arm_group_label>
    <arm_group_label>Placebo Non-responders Re-randomized to Treatment</arm_group_label>
    <arm_group_label>Placebo Responders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women of any ethnic origin&#xD;
&#xD;
          2. Written informed consent is obtained&#xD;
&#xD;
          3. Speaks and writes in English&#xD;
&#xD;
          4. A willingness and ability to comply with study procedures.&#xD;
&#xD;
          5. Age 25-75 years&#xD;
&#xD;
          6. Diagnosis of Type 2 diabetes with suboptimally controlled blood sugar determined by&#xD;
             HbA1c &gt; 6.5% (and &lt; 10.0%) at both the screening and randomization visits&#xD;
&#xD;
          7. No changes in diabetes medication in the previous month&#xD;
&#xD;
          8. DSM-5 criteria for Insomnia Disorder&#xD;
&#xD;
          9. Score on the Insomnia Severity Index (ISI) measure &gt;10, indicating at least a moderate&#xD;
             level of insomnia symptoms2&#xD;
&#xD;
         10. Report a total sleep time ≤ 6.5 hours and combined sleep onset latency (SOL) and wake&#xD;
             after sleep onset (WASO) &gt; 45 minutes on 7 or more of the 14 nightly sleep logs during&#xD;
             both the initial 2-week screening period and the two-week screening run-in period.&#xD;
             Combined SOL and WASO does not decrease by more than 50% on the 2-week sleep diary&#xD;
             obtained between the screening visit and the randomization visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Sleep and medical factors:&#xD;
&#xD;
               1. Diagnosis of severe obstructive sleep apnea not using CPAP (can be included if&#xD;
                  CPAP adherent), or other untreated primary sleep disorders (e.g. narcolepsy,&#xD;
                  moderate to severe restless legs syndrome)&#xD;
&#xD;
               2. Shift workers&#xD;
&#xD;
               3. Use of hypnotic medications more than twice per week in the past month&#xD;
&#xD;
               4. Unwillingness to not use sedative-hypnotics (other than suvorexant) during the&#xD;
                  study period&#xD;
&#xD;
               5. Unwillingness to maintain stable diabetes medication during the study unless&#xD;
                  medically indicated&#xD;
&#xD;
               6. Positive urine toxic screen for any drugs of abuse other than marijuana at&#xD;
                  Screening Visit&#xD;
&#xD;
               7. HbA1c ≥ 10.0% at either the screening or randomization visit&#xD;
&#xD;
          2. Psychiatric factors:&#xD;
&#xD;
               1. Current major depressive episode, by report and as indicated by the Quick&#xD;
                  Inventory of Depressive Symptoms-Self Report (QIDS-SR).&#xD;
&#xD;
               2. Subjects with active or unstable major psychiatric disorder, who, in the&#xD;
                  investigator's judgement, require further treatment.&#xD;
&#xD;
               3. Current alcohol/substance use disorder&#xD;
&#xD;
          3. Medical factors:&#xD;
&#xD;
               1. Renal or hepatic disease judged to interfere with drug metabolism and excretion&#xD;
&#xD;
               2. Pregnant or breastfeeding&#xD;
&#xD;
               3. Malignancy within past 2 years&#xD;
&#xD;
               4. Surgery within past 3 months&#xD;
&#xD;
               5. Neurological disorder or cardiovascular disease raising safety concerns about use&#xD;
                  of suvorexant and/or judged to interfere with ability to assess efficacy of the&#xD;
                  treatment&#xD;
&#xD;
               6. Medical instability considered to interfere with study procedures&#xD;
&#xD;
               7. Concomitant medications with drug interaction or co-administration concerns&#xD;
&#xD;
               8. Contraindications or allergic responses to suvorexant&#xD;
&#xD;
               9. History of being treated with suvorexant&#xD;
&#xD;
          4. Lifestyle and other factors:&#xD;
&#xD;
               1. Travel across two time-zones during the week prior to enrollment&#xD;
&#xD;
               2. Greater than 6 cups of coffee per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Winkelman, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>John Winkelman, MD, PhD</investigator_full_name>
    <investigator_title>Chief, Sleep Disorders Clinical Research Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

